Ads
related to: genetic testing for color blindness
Search results
Results from the WOW.Com Content Network
The first retinal gene therapy to be approved by the FDA was Voretigene neparvovec in 2017, which treats Leber's congenital amaurosis, a genetic disorder that can lead to blindness. These treatments also use subretinal injections of AAV vector and are therefore foundational to research in gene therapy for color blindness. [2] [3]
Rarer genetic conditions causing color blindness include congenital blue–yellow color blindness (tritan type), blue cone monochromacy, and achromatopsia. Color blindness can also result from physical or chemical damage to the eye, the optic nerve, parts of the brain, or from medication toxicity. [2] Color vision also naturally degrades in old ...
These color vision tests test detect the color vision phenotype, and not the subject genotype, so are unable to differentiate acquired from congenital red–green color blindness. However, color vision and genotype are highly correlated, especially when acquired color blindness is ruled out. [16]
Gene therapy is a general treatment for genetic disorders; it uses viral vectors to carry typical genes into cells (e.g. cone cells) that are not able to express functional genes (e.g. photopsins). It may be possible to restore color vision by adding missing opsin genes – or a functional copy of the entire gene complex – into the cone cells.
Molecular diagnosis can be established by identification of biallelic variants in the causative genes. Molecular genetic testing approaches used in achromatopsia can include targeted analysis for the common CNGB3 variant c.1148delC (p.Thr383IlefsTer13), use of a multigenerational panel, or comprehensive genomic testing. [citation needed]
The costs of genetic testing vary depending on the type and complexity of the test. According to health experts, genetic test costs range from $100 to more than $2,000 without coverage.
People with RM have a reduced visual acuity, (usually about 0.1 or 20/200), have total color blindness, photo-aversion and nystagmus. The nystagmus and photo-aversion usually are present during the first months of life, and the prevalence of the disease is estimated to be 1 in 30,000 worldwide. [ 3 ]
Retinal gene therapy holds a promise in treating different forms of non-inherited and inherited blindness. In 2008, three independent research groups reported that patients with the rare genetic retinal disease Leber's congenital amaurosis had been successfully treated using gene therapy with adeno-associated virus (AAV).
Ads
related to: genetic testing for color blindness